en · de · es · fr · pt
ipamorelin-notes.peptides8425.com › Info › Ipamorelin Background And Pharmacology — Questions and Answers

Ipamorelin Background And Pharmacology — Questions and Answers

By Editorial Desk · published 2026-01-31 · last reviewed 2026-02-17 · Info

secretagogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-02-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

Ipamorelin Background and Pharmacology

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.

At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.

Receptor Mechanism and Secretagogue Action

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

Ipamorelin at a glance

PropertyValueNotes
Chemical classSynthetic pentapeptideGrowth hormone secretagogue family
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2Contains two non-natural residues
Molecular formulaC38H49N9O5Free base form
Molecular weight711.85 g/molCalculated from formula
Primary targetGHS-R1a ghrelin receptorAgonist activity

Handling, Storage, and Analytical Characterization

Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.

Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.

Related pages on this site

Handling, Stability and Analytical Verification

Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.

Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.

Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.

Background And Receptor Mechanism

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Ipamorelin Background and Receptor Selectivity

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Supporting material

=== United States === In the U.S., laboratory mice are not regulated under the Animal Welfare Act administered by the USDA APHIS. However, the Public Health Service Act (PHS) as administered by the National Institutes of Health does offer a standard for their care and use. Compliance with the PHS is required for a research project to receive federal funding. PHS policy is administered by the Office of Laboratory Animal Welfare. Many academic research institutes seek accreditation voluntarily, often through the Association for Assessment and Accreditation of Laboratory Animal Care, which maintains the standards of care found within The Guide for the Care and Use of Laboratory Animals and the PHS policy. This accreditation is, however, not a prerequisite for federal funding, unlike the actual compliance.

In the winter, moist air from the Atlantic condenses in the cold continental interior, resulting in overcast conditions. However, this same continental influence results in sunnier summers than oceanic cities of similar latitude such as Edinburgh. Between 2004 and 2010, the average sunshine received varied between 1800 and 2000 hours, with a tendency toward more sunshine in summer months—up to a record 411 hours in July 2014, which represented 79% of potential sunshine. December 2017 was the darkest month in Moscow since records began, with only six minutes of sunlight. Temperatures in the center of Moscow are often higher than in the outskirts and nearby suburbs, especially during winter. For example, if the average January temperature in the northeast of Moscow is −6.2 °C (20.8 °F), in the suburbs it is about −8.3 °C (17.1 °F). The temperature difference between the center of Moscow and nearby areas of Moscow Oblast can sometimes be more than 10 °C (18 °F) on frosty winter nights.

Ménière's disease "Biologic disease-modifying antirheumatic drugs" This may not happen in the absence of infection. Atlanto-axial joint instability can cause symptoms including vertigo and sudden death. Atypical Cogan's syndrome may be associated with rheumoatoid arthritis.

{\displaystyle {\boldsymbol {\sigma }}={\begin{bmatrix}-p+{\cfrac {\mu J_{m}(1+\gamma ^{2})}{J_{m}-\gamma ^{2}}}&{\cfrac {\mu J_{m}\gamma }{J_{m}-\gamma ^{2}}}&0\\{\cfrac {\mu J_{m}\gamma }{J_{m}-\gamma ^{2}}}&-p+{\cfrac {\mu J_{m}}{J_{m}-\gamma ^{2}}}&0\\0&0&-p+{\cfrac {\mu J_{m}}{J_{m}-\gamma ^{2}}}\end{bmatrix}}}

Sources: en.wikipedia.org

Notes from published material

However the amino acid tree seems to be more likely since it appears to be free from the synonymous codon-family bias affecting the nucleotide one. Most of the inferences based on amino acids sequences support a clade which includes Branchiopoda, Remipedia, Copepoda and Hexapoda (group A). Using the best amino acids substitution model, CATGTR, also Cephalocarida falls inside this group. In all the analyses group A (with or without Cephalocarida) is sister-group of a clade composed by Malacostraca, Oligostraca and Thecostraca (group B). The following diagram shows the tree resulting from the Dayhoff recoding.

In another, there is a wider reaction, involving the blood or other organs. This is called a systemic allergy. The result can be hives or red patches all over the skin or may feel changes in heart rate or breathing rate. A doctor may treat the underlying allergy by prescribing purified insulins or by desensitization. The acute symptoms may also require treatment, possibly by anti-histamines. See also: Desensitization. Insulin antagonists Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it. Glucagon is, therefore, an antagonist of insulin. Insulin binding When insulin attaches itself to something else. This can occur in two ways. First, when a cell needs energy, insulin can bind with a special purpose receptor on the surface of a cell (about 2/3 of human body cells, including muscles, but not including nerve cells). The cell then can bring glucose (sugar) inside; thus enabling energy production in the cell. Some cells can store glucose internally (liver cells and muscle cells primarily), but others, most importantly, nerve cells, cannot. With the help of insulin, the cell can absorb 'fuel' and proceed to do its work. But sometimes the body acts against itself. In this second case, the insulin binds with the proteins that are supposed to tag antigens (substances or fragments of cells) which are foreign to the body (i.e., antibodies). If the insulin is an injected form and not made internally, the body may see the insulin as an outside or "foreign" substance.

Amitabha Chattopadhyay is an Indian scientist working in the areas of membrane and receptor biology and biophysics . He is presently a CSIR Bhatnagar Fellow at the Center for Cellular and Molecular Biology and served as the founding dean of biological sciences at the Academy of Scientific and Innovative Research (AcSIR). In addition, he is a distinguished visiting professor at the Indian Institute of Technology Bombay, adjunct professor at the Jawaharlal Nehru University (New Delhi), Tata Institute of Fundamental Research, Indian Institute of Science Education and Research (Kolkata), Swinburne University of Technology (Australia), and honorary professor at the Jawaharlal Nehru Centre for Advanced Scientific Research (Bangalore). He was elected a Fellow of the Royal Society of Chemistry in 2013 and Royal Society of Biology in 2017. Chattopadhyay has authored more than 300 research papers and has an h-index of 65. In 2016, Chattopadhyay won The World Academy of Sciences in Biology for his seminal contribution in understanding the role of membrane cholesterol in the organization and function in healthy and diseased conditions.

Sources: en.wikipedia.org

Further detail

=== Legal status === Dasiglucagon was designated an orphan drug by the FDA in August 2017. In May 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zegalogue, intended for the treatment of severe hypoglycaemia in people with diabetes. The applicant for this medicinal product is Zealand Pharma A/S. Dasiglucagon was approved for medical use in the European Union in July 2024.

== Further reading == Huang, T. C.; Teng, D. F. (2004). "Soy Sauce". Handbook of Food and Beverage Fermentation Technology. doi:10.1201/9780203913550.ch29 (inactive 12 July 2025). ISBN 978-0-8247-4780-0.{{cite book}}: CS1 maint: DOI inactive as of July 2025 (link)—on the production of soy sauce

From January 1968 onward there would be two yearly intakes of national servicemen undergoing nine months of military training. The air strike on Sacatxai also marked a fundamental shift in South African tactics, as the SADF had for the first time indicated a willingness to strike at SWALA on foreign soil. Although Angola was then an overseas province of Portugal, Lisbon granted the SADF's request to mount punitive campaigns across the border. In May 1967 South Africa established a new facility at Rundu to coordinate joint air operations between the SADF and the Portuguese Armed Forces, and posted two permanent liaison officers at Menongue and Cuito Cuanavale. As the war intensified, South Africa's case for annexation in the international community continued to decline, coinciding with an unparalleled wave of sympathy for SWAPO. Despite the ICJ's advisory opinions to the contrary, as well as the dismissal of the case presented by Ethiopia and Liberia, the UN declared that South Africa had failed in its obligations to ensure the moral and material well-being of the indigenous inhabitants of South West Africa, and had thus disavowed its own mandate. The UN thereby assumed that the mandate was terminated, which meant South Africa had no further right to administer the territory, and that henceforth South West Africa would come under the direct responsibility of the General Assembly. The post of United Nations Commissioner for South West Africa was created, as well as an ad hoc council, to recommend practical means for local administration.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is ipamorelin?

It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.

Which receptor does ipamorelin act on?

It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.

How does it differ from other secretagogues?

Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.

What receptor does ipamorelin act on?

It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.

Network